Informace o publikaci

Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary

Autoři	SINGH S. CARNAGHI C. BUZZONI R. POMMIER R.F. RADERER M. TOMÁŠEK Jiří LAHNER H. VALLE J.W. VOI M. BUBUTEISHVILI-PACAUD L. LINCY J. WOLIN E. OKITA N. LIBUTTI S.K. OH D.Y. KULKE M. STROSBERG J. YAO J.C. PAVEL M.E. FAZIO N.
Rok publikování	2018
Druh	Článek v odborném periodiku
Časopis / Zdroj	NEUROENDOCRINOLOGY
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Doi	http://dx.doi.org/10.1159/000477585
Klíčová slova	Everolimus; Neuroendocrine tumors; RADIANT-4 study; Gastrointestinal tract
Popis	Purpose: The RADIANT-4 randomized phase 3 study demonstrated significant prolongation of median progression-free survival (PFS) with everolimus compared to placebo (11.0 [95% CI 9.2-13.3] vs. 3.9 [95% CI 3.6-7.4] months) in patients with advanced, progressive, nonfunctional gastrointestinal (GI) and lung neuroendocrine tumors (NET). This analysis specifically evaluated NET patients with GI and unknown primary origin. Methods: Patients in the RADIANT-4 trial were randomized 2: 1 to everolimus 10 mg/day or placebo. The effect of everolimus on PFS was evaluated in patients with NET of the GI tract or unknown primary site. Results: Of the 302 patients enrolled, 175 had GI NET (everolimus, 118; placebo, 57) and 36 had unknown primary (everolimus, 23; placebo, 13). In the GI subset, the median PFS by central review was 13.1 months (95% CI 9.2-17.3) in the everolimus arm versus 5.4 months (95% CI 3.6-9.3) in the placebo arm; the hazard ratio (HR) was 0.56 (95% CI 0.37-0.84). In the unknown primary patients, the median PFS was 13.6 months (95% CI 4.1-not evaluable) for everolimus versus 7.5 months (95% CI 1.9-18.5) for placebo; the HR was 0.60 (95% CI 0.24-1.51). Everolimus efficacy was also demonstrated in both midgut and non-midgut populations; a 40-46% reduction in the risk of progression or death was reported for patients in the combined GI and unknown primary subgroup. Everolimus had a benefit regardless of prior somatostatin analog therapy. Conclusions: Everolimus showed a clinically meaningful PFS benefit in patients with advanced progressive nonfunctional NET of GI and unknown primary, consistent with the overall RADIANT-4 results, providing an effective new standard treatment option in this patient population and filling an unmet treatment need for these patients. (c) 2017 S. Karger AG, Basel